kmi-429 and Alzheimer-Disease

Recently, we reported potent and small-sized beta-secretase (BACE1) inhibitors KMI-420 and KMI-429 in which we replaced the Glu residue at the P4 position of KMI-260 and KMI-360, respectively, with a 1H-tetrazole-5-carbonyl DAP (L-alpha,beta-diaminopropionic acid) residue. At the P1' position, these compounds contain one or two carboxylic acid groups, which are unfavorable for crossing the blood-brain barrier. Herein, we report BACE1 inhibitors with P1' carboxylic acid bioisosteres in order to develop practical anti-Alzheimer's disease drugs. Among them, tetrazole ring-containing compounds, KMI-570 (IC50=4.8 nM) and KMI-684 (IC50=1.2 nM), exhibited significantly potent BACE1 inhibitory activities.

Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Carboxylic Acids; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Endopeptidases; Enzyme Inhibitors; Models, Molecular; Molecular Structure; Oligopeptides; Stereoisomerism; Structure-Activity Relationship